KMDA - Kamada logo

Kamada manufactures and sells plasma-derived protein therapeutics, including treatments for rabies, cytomegalovirus, asthma, and various immunodeficiencies. The company also distributes biopharmaceutical products in Israel for multiple medical conditions.

โš•๏ธ Healthcare NASDAQ Listed 2013 $ USD
$1,000 invested 10 years ago โ†’$1,784today

Score Overview

1 Year
Score
Net Growth0.83%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth0.68%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score8.2
Net Growth11x
Net Trend80%
Net Income Consistencyโ€”
Rev Growth75.30%
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Score
Net Growth402.48%
Net Trend60%
Net Income Consistency
Rev Growth134.45%
Rev Trend90%
Revenue Consistency
All Time
Score
Net Growth45x
Net Trend62%
Net Income Consistency
Rev Growth157.26%
Rev Trend85%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Kamada has ranked, year by year

Measure
Fundamentals Window

Showing 5 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • KMDA

2019: 15.7% ยท 2021: 19.2% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-30
$ 8.46โ€”
1 Year2025-09-30
$ 6.6028.20%
5 Years2021-09-30
$ 4.9072.67%
10 Years2016-09-30
$ 4.7478.40%
All Time2013-05-31
$ 9.33-9.34%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 181M$ 20M$ 73M
2025$ 180M$ 20M$ 75M
2024$ 160M$ 14M$ 78M
2023$ 142M$ 8M$ 55M
2022$ 129M-$ 2M$ 34M
2021$ 103M-$ 2M$ 18M
2020$ 133M$ 17M$ 109M
2019$ 127M$ 22M$ 73M
2018$ 114M$ 22M$ 50M
2017$ 102M$ 6M$ 43M
2016$ 77M-$ 6M$ 28M
2015$ 70M-$ 11M$ 28M
2014$ 71M-$ 12M$ 51M
IPO2013$ 70M$ 443K$ 74M
KMDA - Kamada logo

Kamada fundamental performance

Between 2020 and 2025, revenue grew from $ 133M to $ 180M and net income grew from $ 17M to $ 20M. Revenue increased in every one of those 5 years; net income in 4.

Across Kamada's full reported history, from 2013 to 2025, revenue grew from $ 70M to $ 180M and net income grew from $ 443K to $ 20M. Revenue increased in 85% of the years measured; net income in 62%.

Kamada currently holds a 5-year HDB Score of 8.2 out of 10. How the HDB Score is calculated.

Membership

Continue KMDAโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies